NCT07126119 - Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2030

Conditions

Upper Tract Urothelial CarcinomaNeoadjuvant TherapyPD-1 InhibitorNab-paclitaxel

Interventions

DRUG

Nab-Paclitaxel

Nab-Paclitaxel 125mg/m\^2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles

DRUG

Tislelizumab

Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.

PROCEDURE

Radical nephroureterectomy (RNU)

Radical nephroureterectomy (RNU) will conducted after the completion of neoadjuvant therapy.

Trial Locations (1)

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Second Hospital

OTHER